Literature DB >> 19926773

Full-length characterization of proteins in human populations.

Chad R Borges1, Doug S Rehder, Jason W Jarvis, Mathew R Schaab, Paul E Oran, Randall W Nelson.   

Abstract

BACKGROUND: Diversity in human proteins often gives rise to pluralities of structurally similar but functionally distinct proteins. Such microheterogeneity generally escapes proteomics discovery technologies, as well as conventional immunometric assays. As an intermediate between these 2 technological approaches, targeted, full-length characterization of proteins using mass spectrometry is a suitable means of defining microheterogeneity evident in human populations. CONTENT: We describe and explore the implications of microheterogeneity using the exemplar of human vitamin D binding protein (Gc-Globulin) as observed in cohorts of 400 individuals. Our investigations yielded: (a) population frequency data comparable to genotyping; (b) population frequency data for protein variants, with and without genotype linkage; (c) reference values for the different protein variants per cohort and genotype; and (d) associations between variant, frequency, relative abundance, and diseases.
SUMMARY: With the exception of the genotype frequency, such population data are unique and illustrate a need to more fully understand the exact full-length qualitative and quantitative idiosyncrasies of individual proteins in relation to health and disease as part of the standardized biomarker development and clinical proteomic investigation of human proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19926773     DOI: 10.1373/clinchem.2009.134858

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

Review 1.  Mass spectrometric immunoassay revisited.

Authors:  Randall W Nelson; Chad R Borges
Journal:  J Am Soc Mass Spectrom       Date:  2011-03-08       Impact factor: 3.109

Review 2.  Exploring the feasibility of bioaerosol analysis as a novel fingerprinting technique.

Authors:  Josemar A Castillo; Sarah J R Staton; Thomas J Taylor; Pierre Herckes; Mark A Hayes
Journal:  Anal Bioanal Chem       Date:  2012-02-04       Impact factor: 4.142

3.  Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm.

Authors:  Mary F Lopez; David A Sarracino; Amol Prakash; Michael Athanas; Bryan Krastins; Taha Rezai; Jennifer N Sutton; Scott Peterman; Oksana Gvozdyak; Sherry Chou; Eng Lo; Ferdinand Buonanno; MingMing Ning
Journal:  Proteomics Clin Appl       Date:  2012-04       Impact factor: 3.494

4.  Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies.

Authors:  Amol Prakash; Taha Rezai; Bryan Krastins; David Sarracino; Michael Athanas; Paul Russo; Hui Zhang; Yuan Tian; Yan Li; Vathany Kulasingam; Andrei Drabovich; Christopher R Smith; Ihor Batruch; Paul E Oran; Claudia Fredolini; Alessandra Luchini; Lance Liotta; Emanuel Petricoin; Eleftherios P Diamandis; Daniel W Chan; Randall Nelson; Mary F Lopez
Journal:  J Proteome Res       Date:  2012-07-03       Impact factor: 4.466

5.  Advances and challenges in biomarker development for type 1 diabetes prediction and prevention using omic technologies.

Authors:  Colleen Carey; Sharad Purohit; Jin-Xiong She
Journal:  Expert Opin Med Diagn       Date:  2010-09-01

6.  Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity.

Authors:  Chad R Borges; Paul E Oran; Sai Buddi; Jason W Jarvis; Matthew R Schaab; Douglas S Rehder; Stephen P Rogers; Thomas Taylor; Randall W Nelson
Journal:  Clin Chem       Date:  2011-03-14       Impact factor: 8.327

7.  Intrapersonal and populational heterogeneity of the chemokine RANTES.

Authors:  Paul E Oran; Nisha D Sherma; Chad R Borges; Jason W Jarvis; Randall W Nelson
Journal:  Clin Chem       Date:  2010-09       Impact factor: 8.327

8.  Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients.

Authors:  Anne Julie Overgaard; Tine E Thingholm; Martin R Larsen; Lise Tarnow; Peter Rossing; James N McGuire; Flemming Pociot
Journal:  Clin Proteomics       Date:  2010-09-10       Impact factor: 3.988

Review 9.  Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes.

Authors:  Hussein Yassine; Chad R Borges; Matthew R Schaab; Dean Billheimer; Craig Stump; Peter Reaven; Serrine S Lau; Randall Nelson
Journal:  Proteomics Clin Appl       Date:  2013-07-09       Impact factor: 3.494

10.  Introduction: Advances in protein analysis for the clinical laboratory.

Authors:  Glen L Hortin; Steven A Carr; N Leigh Anderson
Journal:  Clin Chem       Date:  2009-11-12       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.